Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Iftikhar Kullo

Cardiovascular Disease Milwaukee, WI Medical Doctor

NPI 1104890581 CMS profile 480434

9200 W Wisconsin Ave, Milwaukee, WI 53226

Open in the dashboard

General payments

$11,215

10 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$299,654 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Iftikhar Kullo of Milwaukee, WI is reported in the CMS Open Payments database as having received $11,215 across 10 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $299,654 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,647 2
2024 General $1,556 2
2023 General $1,500 1
2021 General $2,250 2
2020 General $750 1
2019 General $3,512 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Iftikhar Kullo
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Iftikhar Kullo were reported at $1,647. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Iftikhar Kullo Cardiovascular Disease median Middle half National median
2019 $3,512 $450 $127–$1,392 $163
2020 $750 $242 $77–$751 $114
2021 $2,250 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $1,500 $443 $136–$1,283 $160
2024 $1,556 $450 $136–$1,323 $164
2025 $1,647 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. FUKUDA DENSHI Co., Ltd. $5,397 5 payments
  2. Roche Diabetes Care GmbH $3,500 1 payment
  3. Kaneka Pharma America LLC $1,500 1 payment
  4. Fukuda Denshi Co., Ltd. $750 1 payment
  5. Amgen Inc. $56 1 payment
  6. Regeneron Healthcare Solutions, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $5,000 2 payments
  2. Travel and Lodging $3,000 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 1 payment
  4. Honoraria $1,500 2 payments
  5. Food and Beverage $202 2 payments
  6. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. VS-2000 $5,397 5 payments
  2. DC ACCU-CHEK Diabetes Management Solutions, Cables, Software, Kits and Accessories $3,500 1 payment
  3. LIPOSORBER $1,500 1 payment
  4. PRALUENT $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

206

Median for Cardiology: 2,533

Drug cost

$98,644

Median for Cardiology: $485,213

Branded share of claims

61.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 98 $71,112
Praluent Pen Alirocumab Brand 28 $26,159
Ezetimibe Generic 45 $976
Rosuvastatin Calcium Generic 19 $240
Losartan Potassium Generic 16 $156

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$11,516

Medicare's payments for the services billed

Medicare patients

73

Average age 75

Services billed

136

34 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 49%
Atrial fibrillation 48%
Heart failure 44%
Chronic kidney disease 41%
Diabetes 37%
Osteoporosis 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record